Nottingham Centre for Multiple Sclerosis and Neuroinflammation, Department of Neurology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, UK.
Nottingham Centre for Multiple Sclerosis and Neuroinflammation, Department of Neurology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, UK; Division of Clinical Neuroscience, University of Nottingham, UK.
J Neurol Sci. 2021 Dec 15;431:120039. doi: 10.1016/j.jns.2021.120039. Epub 2021 Oct 24.
There are few studies exploring the prognostic factors in patients with aquaporin-4 (AQP4)-IgG positive neuromyelitis optica spectrum disorder (NMOSD).
To assess the predictors of outcome in patients with AQP4-antibody positive NMOSD from a United Kingdom (UK) population.
A retrospective study of 52 patients from 2 neuroscience centres in the UK Midlands.
The most common initial presentations were acute myelitis and optic neuritis, with 22/52 cases (42.3%) each. Relapsing course was seen in 32 patients (61.5%) with mean annualised relapse rate of 0.43 (standard deviation 0.45) and a mean interval time to first relapse of 31 months (range 2-108). The median Expanded Disability Status Scale (EDSS) score at the last follow up was 4 (range 1-9). Age at onset was an independent predictor of disability in the whole cohort of patients with NMOSD. For every 10-year increase in age at disease onset, the risk of developing an EDSS score of ≥4 increased by 34%. Patients who presented initially with a longitudinally extensive transverse myelitis (LETM) showed a higher risk to develop disability, compared to other clinical presentations (median time of 4 years versus 13 years). Late onset (LO-NMOSD) patients were likely to reach an EDSS score of 4 more quickly, compared to early onset (EO-NMOSD) (median time of 7 years versus 13 years). Higher median EDSS score at last follow up was observed in LO-NMOSD compared to EO-NMOSD (6 versus 2).
Increasing age at onset and LETM predict disability in AQP-4-IgG positive NMOSD patients.
目前鲜有研究探讨水通道蛋白 4(AQP4)-IgG 阳性视神经脊髓炎谱系疾病(NMOSD)患者的预后因素。
评估英国(UK)AQP4 抗体阳性 NMOSD 患者的结局预测因素。
对英国中部 2 个神经科学中心的 52 例患者进行回顾性研究。
最常见的首发表现为急性脊髓炎和视神经炎,各有 22/52 例(42.3%)。32 例(61.5%)患者出现复发,年复发率为 0.43(标准差 0.45),首次复发的平均间隔时间为 31 个月(范围 2-108)。末次随访时扩展残疾状况量表(EDSS)评分中位数为 4 分(范围 1-9)。发病年龄是 NMOSD 患者全组残疾的独立预测因素。发病年龄每增加 10 岁,EDSS 评分≥4 的风险增加 34%。与其他临床表现相比,初诊为长节段横贯性脊髓炎(LETM)的患者发生残疾的风险更高(中位时间为 4 年与 13 年)。与早发性 NMOSD(EO-NMOSD)相比,迟发性 NMOSD(LO-NMOSD)患者更有可能在更短的时间内达到 EDSS 评分 4 分(中位时间为 7 年与 13 年)。与 EO-NMOSD 相比,LO-NMOSD 患者末次随访时的中位 EDSS 评分更高(6 分与 2 分)。
发病年龄增加和 LETM 可预测 AQP-4-IgG 阳性 NMOSD 患者的残疾情况。